What is Acticor Biotech?
Acticor Biotech is a specialized biopharmaceutical entity originating as a spin-off from the French National Institute of Health and Medical Research (INSERM). The company is primarily focused on the development of Glenzocimab, a first-in-class drug candidate engineered to treat acute ischemic stroke and other severe thrombotic diseases. By targeting the critical intersection of cardiovascular health and emergency medicine, Acticor Biotech occupies a vital niche in the life sciences market. Their operational model emphasizes rigorous clinical validation and the pursuit of high-impact therapeutic solutions for conditions that currently lack adequate treatment options, thereby addressing a significant unmet medical need on a global scale.
How much funding has Acticor Biotech raised?
Acticor Biotech has raised a total of $12.8M across 4 funding rounds:
Private Equity
$1.5M
Private Equity
$1.6M
Series A
$2M
Series B
$7.6M
Private Equity (2016): $1.5M, investors not publicly disclosed
Private Equity (2017): $1.6M led by Karista
Series A (2018): $2.1M supported by Karista, Anaxago, and Primer Capital
Series B (2019): $7.6M featuring Newton BioCapital, Karista, Go Capital, and Anaxago
Key Investors in Acticor Biotech
Karista
Karista is an independent venture capital firm with two decades of experience backing over 100 companies across Europe, focusing on digital, technology, and healthcare sectors.
Go Capital
A strategic investment firm that acts as an innovation platform, facilitating the integration of advanced technology into global markets with a focus on life sciences and digital sectors.
Anaxago
Anaxago is a prominent investment platform that provides capital and strategic support to innovative companies, focusing on high-growth potential sectors including healthcare and biotechnology.
What's next for Acticor Biotech?
With the successful completion of its latest funding round, Acticor Biotech is poised to transition into a more advanced phase of clinical development. The strategic allocation of these funds will likely prioritize the expansion of clinical trials for Glenzocimab, aiming to solidify its position as a standard-of-care intervention in acute stroke management. Furthermore, the company is expected to leverage its strong investor network to facilitate potential partnerships and market penetration strategies. As the firm continues to mature, the focus will shift toward regulatory milestones and the eventual commercialization of its pipeline, ensuring that its proprietary technology translates into tangible patient outcomes and long-term enterprise value.
See full Acticor Biotech company page
